SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the utility of the PROSTest to predict response to 177 Lu-PSMA therapy in ...

SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the clinical value of the PROSTest to detect biochemical recurrence in ...

Neeraj Agarwal is joined by Wolfgang Fendler to discuss PSMA PET prognostication data. Dr. Fendler's international consortium of 50 sites analyzed 6,000 patients to develop risk stratification models ...

Neeraj Agarwal is joined by Nobuaki Matsubara to discuss final patient-reported outcomes data from the TALAPRO-2 trial. The study evaluated enzalutamide plus talazoparib versus enzalutamide plus ...

Sam Chang interviews Alice Yu about three practice-changing areas in urothelial carcinoma. Dr. Yu first discusses the NIAGARA trial, which demonstrated improved pathologic complete response, ...

Evan Yu is joined by Atish Choudhury to discuss a first-in-human trial combining EZH2 and PARP inhibition in metastatic castration-resistant prostate cancer. Dr. Choudhury explains that EZH2 is an ...

1 Attard, G., et al. (2025, May). Phase 3 AMPLITUDE trial: Niraparib and abiraterone acetate plus prednisone for metastatic castration-sensitive prostate cancer patients with alterations in homologous ...

Bicycle Therapeutics announced two poster presentations at the 2025 ASCO Annual Meeting, featuring preliminary results from the Phase 1/2 Duravelo-1 study evaluating the Nectin-4-targeting Bicycle® ...

Bladder Cancer - Read the latest Bladder Cancer research including Full-Text Abstracts as well as "Beyond the Abstract" articles, written by the researchers exclusively for UroToday.

Erectile Dysfunction - Read the latest Erectile Dysfunction research including Full-Text Abstracts as well as "Beyond the Abstract" articles, written by the researchers exclusively for UroToday.

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a kidney and bladder cancers poster session.

R. Jonathan Henderson summarized key principles for managing biochemically recurrent prostate cancer, emphasizing the importance of risk stratification and life expectancy in treatment decisions.